Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study

Journal of Hypertension

Volumn 24, Issue 11, 2006, Pages 2277-2284

  Pascual, Jose Maria ^a   Rodilla, Enrique ^a   Miralles, Amparo ^a   Gonzalez, Carmen ^a   Redon, Josep ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Blood pressure control; Essential hypertension; Fasting glucose; Glomerular filtration rate; Urinary albumin excretion

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

EID: 33750229528     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000249707.36393.02     Document Type: Article

References (34)

1. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al., The Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249:519-526.
2. Redon J, Baldo E, Lurbe E, Bertolin V, Lozano JV, Miralles A, Pascual JM. Microalbuminuria, left ventricular mass and ambulatory blood pressure monitoring. Kidney Int 1996; 49 (Suppl 55):S81-S84.
3. Pontremoli R, Ravera M, Bezante GP, Viazzi F, Nicolella C, Berruti V, et al. Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 1999; 17:993-1000.
4. Kramer H, Jacobs DR Jr, Bild D, Post W, Saad MF, Detrano R, et al. Urine albumin excretion and subclinical cardiovascular disease. Hypertension 2005; 46:38-43.
5. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16:1325-1333.
6. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19:617-624.
7. Ibsen H, Wachtell K, Olsen MH, Borch-Johsen K, Lindholm LH, Mogensen CE, et al. Does microalbuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22:1805-1811.
8. Ibsen H, Olsen MH, Wachtell K, Borch-Johnnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: a LIFE study. Hypertension 2005; 45:198-202.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
10. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
11. Bakris G. Inclusion of albuminuria in hypertension and heart guidelines. Kidney Int Suppl 2004; 92:S124-S125.
12. Ruilope LM, Alcazar JM, Hernandez E, Rodicio JL. Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int 1994; 45 (Suppl 45):s171-s173.
13. Sievert-Delle A, Ljungman S, Hartford M, Wikstrand J. Effect of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension. Am J Hypertens 1996; 9:841-849.
14. Redon J, Rovira E, Miralles A, Julve R, Pascual JM. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39:794-798.
15. Pascual JM, Rodilla E, Gonzalez C, Perez-Hoyos S, Redon J. Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension 2005; 45:1125-1130.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
17. StataCorp. Stata Statistical Software: release 8.0. College Station, TX: Stata Corporation; 2003.
18. Redon J, Ruilope LM. Microalbuminuria as an intermediate endpoint in hypertension Evidence is coming. J Hypertens 2004; 22:1689-1691.
19. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002; 137:563-570.
20. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681-689.
21. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalisation. N Engl J Med 2004; 351:1296-1306.
22. Redon , Pascual . Factors related to the development of microalbuminuria in essential hypertension. Curr Hypertens Rep 2006; 8:171-177.
23. Minram A, Ribstein J, DuCailar G. Is microalbuminuria a marker of early intrarenal vascular damage in essential hypertension? Hypertension 1994; 23:878-883.
24. Mountolakis TD. The renal consequences of essential hypertension. Kidney Int 1997; 51:1639-1653.
25. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Catapano G, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344:14-18.
26. Taddei S, Virdis A, Ghiadoni L, Salvetti G, Salvetti A. Endothelial dysfunction in hypertension. J Nephrol 2000; 13:205-210.
27. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951.
28. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggresive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086-1097.
29. Redon J, Miralles A, Liao Y, Lozano JV, Pascual JM, Cooper RS. Circadian variability and microalbuminuria in essential hypertension. J Hypertens 1994; 12:947-954.
30. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in Type 1 diabetes. N Engl J Med 2002; 347:797-805.
31. Meigs JB, D'Agostino RB, Nathan DM, Rifai N, Wilson PWF. Longitudinal association of glycemia and microalbuminuria: The Framingham Offspring Study. Diabetes Care 2002; 25:977-983.
32. Meigs JB, Nathan DM, Wilson PWF, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: The Framingham Offspring Study. Ann Intern Med 1998; 128:524-533.
33. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165:947-953.
34. Redon J. Urinary albumin excretion: lowering the threshold of risk in hypertension. Hypertension 2005; 46:19-20.